Apollo Biowellness, Inc., f/k/a Resonate Blends, Inc., Corporate Update
Apollo Biowellness (OTC Pink: KOAN), formerly Resonate Blends, has announced several key business developments. The company has achieved full compliance with its filings and is preparing for OTCIQ listing. The company has successfully negotiated with creditors and is finalizing exclusive distribution agreements for its Evolutionary Biologics Brand across multiple regions.
Apollo is planning to launch a shelf-stabilized consumer cosmetic product through retail and e-commerce channels within the next few quarters. Management expects significant growth with international sales beginning in Q3 and Q4 2025.
Apollo Biowellness (OTC Pink: KOAN), precedentemente nota come Resonate Blends, ha annunciato importanti sviluppi aziendali. L'azienda ha completato con successo tutte le procedure di conformità per le sue dichiarazioni e si sta preparando per la quotazione su OTCIQ. Inoltre, ha negoziato con successo con i creditori e sta finalizzando accordi esclusivi di distribuzione per il suo marchio Evolutionary Biologics in diverse regioni.
Apollo prevede di lanciare un prodotto cosmetico da banco stabile sugli scaffali, disponibile tramite canali retail e e-commerce, entro i prossimi trimestri. La direzione si aspetta una crescita significativa con l'inizio delle vendite internazionali nel terzo e quarto trimestre del 2025.
Apollo Biowellness (OTC Pink: KOAN), anteriormente Resonate Blends, ha anunciado varios avances clave en su negocio. La empresa ha cumplido completamente con sus presentaciones regulatorias y se está preparando para su listado en OTCIQ. Además, ha negociado exitosamente con sus acreedores y está finalizando acuerdos exclusivos de distribución para su marca Evolutionary Biologics en múltiples regiones.
Apollo planea lanzar un producto cosmético de consumo con estabilidad en estantería a través de canales minoristas y de comercio electrónico en los próximos trimestres. La gerencia espera un crecimiento significativo con ventas internacionales que comenzarán en el tercer y cuarto trimestre de 2025.
Apollo Biowellness (OTC Pink: KOAN), 이전의 Resonate Blends, 여러 주요 사업 발전 사항을 발표했습니다. 회사는 모든 신고 의무를 완전히 준수했으며 OTCIQ 상장을 준비 중입니다. 또한 채권자들과 성공적으로 협상하였고, Evolutionary Biologics 브랜드의 독점 유통 계약을 여러 지역에서 마무리하고 있습니다.
Apollo는 향후 몇 분기 내에 소매 및 전자상거래 채널을 통해 선반 안정화된 소비자용 화장품 제품을 출시할 계획입니다. 경영진은 2025년 3분기와 4분기부터 시작되는 국제 판매와 함께 상당한 성장을 기대하고 있습니다.
Apollo Biowellness (OTC Pink : KOAN), anciennement Resonate Blends, a annoncé plusieurs développements clés. La société a atteint une conformité totale dans ses dépôts réglementaires et se prépare à une cotation sur OTCIQ. Elle a également négocié avec succès avec ses créanciers et finalise des accords exclusifs de distribution pour sa marque Evolutionary Biologics dans plusieurs régions.
Apollo prévoit de lancer un produit cosmétique grand public stable en rayon via des canaux de vente au détail et en ligne dans les prochains trimestres. La direction anticipe une croissance significative avec des ventes internationales débutant au troisième et quatrième trimestre 2025.
Apollo Biowellness (OTC Pink: KOAN), ehemals Resonate Blends, hat mehrere wichtige geschäftliche Entwicklungen bekannt gegeben. Das Unternehmen hat alle erforderlichen Meldungen vollständig eingereicht und bereitet sich auf die Notierung bei OTCIQ vor. Zudem wurden erfolgreiche Verhandlungen mit Gläubigern geführt, und exklusive Vertriebsvereinbarungen für die Marke Evolutionary Biologics in mehreren Regionen stehen kurz vor dem Abschluss.
Apollo plant, in den nächsten Quartalen ein haltbares kosmetisches Verbraucherprodukt über Einzelhandels- und E-Commerce-Kanäle auf den Markt zu bringen. Das Management erwartet ab dem dritten und vierten Quartal 2025 ein bedeutendes Wachstum durch internationale Verkäufe.
- Company has achieved full compliance with filings and preparing for OTCIQ listing
- Successfully negotiated arrangements with creditors
- Finalizing exclusive distribution deals for North America with plans for international expansion
- New shelf-stabilized consumer cosmetic product launch planned for Q3 2025
- Company currently trades on OTC Pink market, indicating lower tier listing
- Previous creditor issues required negotiations
- Product launches and distribution deals are still pending, not finalized
North Bergen, New Jersey--(Newsfile Corp. - June 26, 2025) - Apollo Biowellness, Inc. formerly known as Resonate Blends, Inc. (OTC Pink: KOAN) (the "Company"), announces that it is fully compliant and is current in its filing. The Company is preparing to be listed on OTCIQ and is pleased to also announce that it has successfully made arrangements with various creditors to allow the Company to move forward and is now in the final stages to execute final exclusive distribution deals in North America, imminently and then later Europe, Middle East and Asia and Latin America on our Evolutionary Biologics Brand.
The Company is also planning, within the next couple of fiscal quarter, on launching a shelf stabilized consumer cosmetic direct to consumers through various retain outlets and e-commerce distribution channels.
James W. Zimbler, President, stated, "With these exciting new plans we expect to see enormous growth and will expect to be selling our products internationally starting in the third and fourth quarters. We are diligently working with various partners in developing the shelf stable consumer branded product, which we are excited to launch before the end of the third quarter and will be announced shortly."
About Apollo Biowellness, Inc. f/k/a Resonate Blends, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
www.evobiologics.com
jzimbler@emergenthealthcorp.com
631-806-1420
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256855
FAQ
What is the current status of Apollo Biowellness (KOAN) compliance and listing?
What are Apollo Biowellness's (KOAN) expansion plans for 2025?
When will Apollo Biowellness (KOAN) launch its new consumer cosmetic product?
What is the relationship between Apollo Biowellness and Resonate Blends?
What progress has KOAN made with its creditors?
